Pregnancy outcomes and prognosis after in vitro fertilization with fertility-sparing surgery for patients with borderline ovarian tumor
10.3969/j.issn.1672-8467.2025.04.008
- VernacularTitle:卵巢交界性肿瘤患者行辅助生殖技术的助孕结局及肿瘤转归
- Author:
Rong-min WANG
1
;
Min YU
;
Xiao-yong ZHU
Author Information
1. 复旦大学附属妇产科医院妇科 上海 200090
- Publication Type:Journal Article
- Keywords:
borderline ovarian tumor(BOT);
controlled ovulation stimulation(COS);
fertility-sparing surgery(FSS);
in vitro fertilization-embryo transfer(IVF-ET)
- From:
Fudan University Journal of Medical Sciences
2025;52(4):525-531
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the pregnancy outcomes and prognosis following in vitro fertilization,and tumor prognosis of infertility patients with borderline ovarian tumor(BOT)after fertility-sparing surgery(FSS).Methods A retrospective study was conducted and 35 infertility patients with BOT after FSS from Shanghai Jiai Genetics and IVF Institute,Obstetrics and Gynecology Hospital,Fudan University were enrolled.The pregnancy outcomes and tumor prognosis were analyzed.Results Among the patients,serous BOT accounted for 62.9％.Twenty-five cases were International Federation of Gynecology and Obstetrics(FIGO)stage Ⅰ,2 stage Ⅱ,and 8 stage Ⅲ.Twelve patients experienced borderline tumor recurrence before assisted reproductive therapy,of which 5 patients were stage Ⅲ and 7 stage Ⅰ.After FSS,the 35 patients firstly underwent controlled ovarian stimulation(COS)at an average interval of(47.3±32.6)months.A total of 79 ovulation induction cycles were taken and mild stimulation protocol was adopted first(41.8％),followed by the natural cycle protocol(25.3％).Twenty-seven patients underwent embryo transfer in 37 cycles,resulting in 21 clinical pregnancies in 19 patients.The clinical pregnancy rate was 56.8％,with a cumulative pregnancy rate of 54.3％.The live birth rate was 43.2％,and the cumulative live birth rate was 42.9％.For patients with anti-Müllerian hormone levels<1.0 ng/mL(n=13),the pregnancy rate was 42.9％,and the cumulative clinical pregnancy rate was 23.1％.Among 30 patients,4(13.3％)patient with stage Ⅲ BOT experienced recurrence,and none had malignant transformation at the median follow-up period of 61 months after the first COS.Conclusion Assisted reproductive technology was safe and could improve pregnancy rates in infertile women with BOT.
